Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies

Acta Haematologica

Volumn 120, Issue 3, 2009, Pages 182-189

  Kim, Yu Ri ^a   Kim, Jin Seok ^b   Cheong, June Won ^b   Song, Jae Woo ^b   Min, Yoo Hong ^b  

^a Kwandong University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Iron overload; Reduced intensity stem cell transplantation; Transfusion

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FERRITIN; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; FERRITIN BLOOD LEVEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VEIN OCCLUSION;

ADOLESCENT; ADULT; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; RISK FACTORS;

EID: 58149142545     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187646     Document Type: Article

References (16)

1. Alt A, Remacha AF, Sureda A, Martino R, Briones J, Canals C, Brunet S, Sierra J, Gimferrer E: Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:987-989.
2. Kamble RT, Selby GB, Mims M, Kharfan-Dabaja MA, Ozer H, George JN: Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:506-510.
3. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ, Antin JH: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586-4588.
4. Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ: Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006;37:857-864.
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B: Graft-versusleukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
6. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ: Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092-1099.
7. Strasser SI, Kowdley KV, Sale GE, McDonald GB: Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 1998;22:167-173.
8. Tomás JF, Pinilla I, García-Buey ML, García A, Figuera A, Gómez-García de Soria VGG, Moreno R, Fernández-Rañada JM: Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 2000;26:649-655.
9. Porter JB: Practical management of iron overload. Br J Haematol 2001;115:239-252.
10. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
11. Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, Tripp JH, Bellon EM: Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-1675.
12. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B: Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000;110:971-977.
13. Morado M, Ojeda E, Garcia-Bustos J, Aguado MJ, Arrieta R, Quevedo E, Navas A, Hernandez-Navarro F: BMT: serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. Hematology 2000;4:505-512.
14. Altes A, Remacha AF, Sarda P, Sancho FJ, Sureda A, Martino R, Briones J, Brunet S, Canals C, Sierra J: Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004;34:505-509.
15. Maertens J, Demuynck H, Verbeken EK, Zachée P, Verhoef GE, Vandenberghe P, Boogaerts MA: Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999;24:307-312.
16. Andrews NC: Disorders of iron metabolism. N Engl J Med 1999;341:1986-1995.